psychedelics – Page 6

Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms

mycolabadmin

Psilocybin, a compound from certain mushrooms, is being studied as a potential rapid-acting treatment for severe depression that doesn’t respond to standard antidepressants. Unlike conventional antidepressants that take weeks to work, psilocybin shows promise for producing mood improvements within days. The drug works by activating serotonin receptors in the brain and promoting the growth of new neural connections, though researchers are still working to fully understand how it achieves its antidepressant effects.

Serotonin and psilocybin activate 5-HT1B receptors to suppress cortical signaling through the claustrum

mycolabadmin

Researchers found that serotonin and psilocybin (the active compound in magic mushrooms) work through the same brain mechanism to suppress certain neural signals in a brain region called the claustrum. This region controls how different parts of the cortex communicate with each other. The study shows that psilocybin directly targets serotonin 5-HT1B receptors to quiet down signals from one brain area to another, which may explain how psychedelics change cortical network activity and alter consciousness.

Prediction of hallucinogen persisting perception disorder and thought disturbance symptoms following psychedelic use

mycolabadmin

Researchers followed 654 people planning to use psychedelics and measured their thinking patterns before and after. They found that delusional thinking actually decreased after use, while about one-third experienced visual effects like seeing trails or intensified colors. However, very few people (less than 1%) found these visual effects bothersome. Younger people, women, and those with psychiatric history were more likely to experience these visual effects.

PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity

mycolabadmin

This study is investigating whether psilocybin (an active compound in magic mushrooms) can help people with obsessive-compulsive disorder (OCD) by improving their mental flexibility and brain plasticity. Participants will receive two doses of psilocybin—a low test dose and a slightly higher therapeutic dose—four weeks apart, while receiving professional psychological support. Researchers will measure changes in cognitive abilities and brain activity to understand how psilocybin might help reduce OCD symptoms like intrusive thoughts and repetitive behaviors.

Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring

mycolabadmin

Researchers tested whether psilocybin could help postpartum depression in mice, but found it actually made things worse for both mothers and their babies. While psilocybin normally reduces depression and anxiety, it had the opposite effect during the postpartum period, making mothers more anxious and disrupting their care of pups. Babies exposed to psilocybin through breastfeeding or direct exposure developed anhedonia (inability to feel pleasure) as adults. These findings suggest that the postpartum period may be a particularly vulnerable time for psychedelic use, and more research is needed before considering these drugs for postpartum depression treatment.

Developmental Neurotoxicity Screen of Psychedelics and Other Drugs of Abuse in Larval Zebrafish (Danio rerio)

mycolabadmin

Researchers tested 13 mind-altering drugs on developing zebrafish to see if they cause birth defects or behavioral problems. They found that psychedelics like psilocybin and ketamine were relatively safe for developing organisms, but traditional drugs of abuse like cocaine and methamphetamine caused significant behavioral changes without obvious physical defects. The study provides important safety information for these compounds, especially for pregnant or nursing individuals considering their use for therapeutic purposes.

Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming

mycolabadmin

Researchers tested whether psilocybin (the active compound in magic mushrooms) could treat obsessive-compulsive disorder using genetically modified mice that exhibit excessive grooming similar to OCD in humans. A single dose of psilocybin or psychedelic mushroom extract significantly reduced the excessive grooming behavior and anxiety in these mice, with benefits lasting up to six weeks. These findings suggest psilocybin may be a promising new treatment for OCD in humans, offering longer-lasting effects from a single dose compared to current medications.

Psilocybin: Systematic review of its use in the treatment of depression

mycolabadmin

Researchers reviewed scientific studies on psilocybin, a psychedelic compound found in certain mushrooms, as a treatment for depression. The studies showed that psilocybin significantly reduced depressive symptoms faster than standard treatments, with minimal side effects. This suggests psilocybin could be a promising new option for people with depression who haven’t benefited from traditional medications.

Scoping Review: The Role of Psychedelics in the Management of Chronic Pain

mycolabadmin

This review examines how psychedelic drugs like LSD and psilocybin might help treat chronic pain conditions such as cluster headaches and phantom limb pain. The researchers found nine studies suggesting these substances could reduce pain by affecting serotonin receptors in the brain. While early results are promising, more rigorous clinical trials are needed before these drugs can become standard pain treatments. The authors note that strict legal restrictions on psychedelics currently limit research opportunities.

Adaptation and latent structure of the Brazilian version of the Ego Dissolution Inventory (EDI-BR): an exploratory study

mycolabadmin

This study adapted a psychological assessment tool called the Ego Dissolution Inventory for use in Brazil. Ego dissolution refers to the profound sense of losing one’s sense of self that people experience when using psychedelics like psilocybin mushrooms and LSD. The researchers found that the adapted Brazilian version works well and identifies three dimensions of the experience: confidence/assertiveness, ego dissolution, and ego inflation. This validated tool can now help researchers in Brazil better understand psychedelic experiences and their potential therapeutic benefits.

Research Topic: psychedelics